new medicine psychedelics

Is This The Next Frontier of Medicine?

Dear Reader,

We’ve come so far with medical science. We can grow a new human ear on the back of a mouse.

We can edit harmful genes out of a sequence with CRISPR technology.

We can even help asthma sufferers handle their condition with Bluetooth-enabled smart inhalers…

But there’s so much we haven’t found answers for yet. There are so many people waging war against mental illness and addiction, and there’s no easy solution for any of the most common disorders.

Check Out These Numbers

Right now…

7-8% of American adults suffer from PTSD.

Major depression affects an estimated 11 million American adults.

A combined 21 million Americans struggle with alcoholism and addiction.

A mind-blowing 40 million Americans suffer from anxiety.

And these aren’t just problems faced by people in the USA. These debilitating mental health disorders are becoming increasingly common around the globe.

Traditional treatment methods like talk therapy and SSRIs (selective serotonin reuptake inhibitors) give some relief, but they tend to take years or even decades to make their mark, leaving sufferers struggling just to make it through.

Now, doctors are trying new methods of treating these problems. One research field in particular is just fascinating.

This new frontier of medicine is bringing back some very old substances and using them in new ways.

I’m talking, of course, about the class of drugs known as psychedelics.

Psychedelics? Really?

Back in the last century, psychedelics were thought of as mind-melting party drugs, with every counter culture from the hippies in the 60’s to the raver kids in the 90’s.

Nowadays, doctors and scientists are meticulously testing the effects of everything from LSD to MDMA (more commonly known as molly or ecstasy) to see how these drugs can alleviate mental health issues.

They’ve found that MDMA can alleviate PTSD in as many as 3 out of 4 cases – this is a result that can’t be replicated with talk therapy. In fact, many sufferers quit talk therapy before they see a benefit because it can be a long, drawn out, and painful affair. Not so when paired with MDMA. This treatment is so effective, the FDA has even designated it as a breakthrough.

Ketamine and psilocybin (which is the main ingredient in what’s colloquially known as magic mushrooms) can short circuit the brain pathways that cause depression. When effective, ketamine works in as few as one to three doses, and psilocybin can provide immediate and prolonged relief with just one use.

And lastly ibogaine (a psychoactive drug derived from a plant found in the rainforests of Africa) can ease the withdrawal symptoms and end the cravings that keep many alcoholics and addicts hooked for life. Rather than spending weeks sweating, shaking and sick with the desire for their next fix, patients treated with ibogaine report no desire to partake again – and again, that’s often after just one treatment.

Just Imagine

Relief from life-destroying, soul-sucking mental illness in days – or even just hours!

Not only is this interesting from a medical standpoint, it’s intriguing from a financial one as well. People in the know are starting to pay attention to these developments because they know it could turn the medical industry on its head.

One such notable investor is Tim Ferriss. Tim is a well known author, entrepreneur, and visionary. Thanks to the success of his books like The Four Hour Work Week and Tribe of Mentors and his long running top-rated podcast, he’s influenced millions of people around the world. He’s purported to have a net wealth of somewhere around $100 Million.

Try and Invest

With all that clout, experience, and wealth, Tim used to only invest in startups. Now, he’s pulled all his attention out of the startup world and put it firmly into the world of psychedelics research.

Never one to put his money into something he hasn’t personally tried, he’s experienced the power of these substances firsthand.

In his book Tools of Titans, he talked at length about his personal use with psychedelics. While some seemed to work better than others for him, he described the outcome as a “hard reboot” for his brain. He credits this for giving him clarity and a bird’s eye view so he can make better decisions for his life and his businesses. That’s pretty crucial for an entrepreneur – and hard to get anywhere else.

It’s more than just personal for Tim, though.

Recently, it’s been revealed that he believes in this psychedelics-as-medicine-trend so much that he’s investing his money into its development. Big time.

Tim’s invested into both a large study on psilocybin for the treatment of depression at Johns Hopkins and – even bigger – he’s a key investor in the world’s first research facility dedicated strictly to the study of psychedelics.

The research facility, located in London, will focus on the potential of turning MDMA, psilocybin, and other psychedelics into real, bona fide medical treatments.

If all goes according to plan, the ramifications of these discoveries could be huge.

After all, antidepressants are poised to grow to $20BIllion in sales worldwide next year. How would a treatment that makes the need for these pills null and void affect Big Pharma’s landscape?

Can you even imagine?

While this may still seem like strange pseudoscience to you, the truth is these new treatments are here to stay, and they could affect just about every aspect of treatment protocols for mental health.

What Does All of This Mean to You?

Well, right now, maybe nothing. But in the future? We could have a world with fewer mental health issues and happier, more productive people. And if you pay close attention, you just might find a way to get in on the ground floor of this new opportunity, too.

After all, if visionaries like Tim Ferriss thinks this is of note, don’t you think maybe it’s worth looking into?


Brian Rose

Brian Rose
Editor, Brian Rose Uncensored

You May Also Be Interested In:

Klaus Schwab’s Prized Pupil Bans Cigarettes

Kiwi Prime Minister Jacinda Ardern announced plans to ban selling tobacco products to anyone born after 2011. Even after these kids turn 18 in 2029, they still will not be able to buy any cigarettes in their home country. Of course, those New Zealanders who have a passing acquaintance with applied economics immediately criticized the...

Brian Rose

Brian Rose is an MIT graduate, with a degree in engineering. Upon finishing school, he immediately began working on Wall Street. An advanced technical trader, Brian was trading a book of $100 million at the age of 22. He spent years on Wall Street, working in New York, Chicago and London. He made millions, but...

View More By Brian Rose